<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735369</url>
  </required_header>
  <id_info>
    <org_study_id>OC10X-CT-BD2 PDR</org_study_id>
    <nct_id>NCT02735369</nct_id>
  </id_info>
  <brief_title>A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR</brief_title>
  <official_title>A Phase II, Randomized, Placebo-Controlled, Study Assessing Efficacy and Safety of OC-10X Ophthalmic Suspension in the Treatment of Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OcuCure Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Semler Research Center Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>OcuCure Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is intended to evaluate the efficacy and safety of topical OC-10X
      Ophthalmic Suspension in patients diagnosed with proliferative diabetic retinopathy (level
      61, 65, 71, or 75). OcuCure Therapeutics, Inc. (Roanoke, VA) has developed a lead compound,
      known as OC-10X, which is a selective tubulin inhibitor under development for the treatment
      of Proliferative Diabetic Retinopathy (PDR) and Age-related Macular Degeneration (AMD). When
      administered as a topical eye drop, OC-10X has both anti-angiogenic (inhibition) and
      angiolytic (regression) properties in animal models of choroidal neovascularization (CNV).
      Unlike other therapies, OC-10X provides the efficacy of a vascular targeting agent without
      the traditional toxicity and works downstream independently of growth factors. As
      demonstrated by OcuCure's preclinical data, tubulin inhibition, using OC-10X, may be a
      promising new approach to the treatment of PDR and AMD. Like AMD, PDR is a major cause of
      blindness in adults and is also caused by the growth of abnormal blood vessels. Importantly,
      the Phase I Study found that OC-10X can be safely applied topically in human eyes without
      adverse ocular or systemic effects.

      Currently, there are few options for the treatment of PDR. Clinical options, such as laser
      photocoagulation or vitrectomy, require surgery and can permanently impair patients' vision.
      With few treatment options available, administration of OC-10X as a topical therapy, along
      with its novel mechanism, has the potential to provide benefits to patients with ocular
      diseases associated with angiogenesis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the mean change of area of neovascularization of the disc (NVD) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the mean change of area of neovascularization of the disc (NVD) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area of neovascularization elsewhere in the retina (NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area of neovascularization elsewhere in the retina (NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area of &quot;Posterior NVE&quot; from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by the change of area change of area of &quot;Posterior NVE&quot; from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by regression of total area of neovascularization (NVD+NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>The effect of OC-10X 2% on regression/inhibition of neovascularization in PDR patients as measured by regression of total area of neovascularization (NVD+NVE) from baseline compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of regression of intraretinal microvascular abnormalities (IRMA) in PDR patients as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of regression of intraretinal microvascular abnormalities (IRMA) in PDR patients as compared to Visit 6 (Week 24)for OC-10X 2% vs. Placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of regression of intraretinal hemorrhage as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of regression of intraretinal hemorrhage as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of regression of venous beading as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of regression of venous beading as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of regression of area of capillary non-perfusion beading as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of regression of area of capillary non-perfusion beading as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of regression of intraretinal exudation (lipid) as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of regression of intraretinal exudation (lipid) as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of regression of macular edema (central subfield thickness) as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of regression of macular edema (central subfield thickness) as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of regression of macular volume as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of regression of macular volume as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of best-corrected ETDRS visual acuity as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of best-corrected ETDRS visual acuity as compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of macular thickness as measured by Optical Coherence Tomography (OCT) compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of macular thickness as measured by Optical Coherence Tomography (OCT) compared to Visit 6 (Week 24) for OC-10X 2% vs. Placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring rescue treatment at the end of the study.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Number of patients requiring rescue treatment at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring pars plana vitrectomy surgery due to presence of vitreous hemorrhage at the end of the study.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Number of patients requiring pars plana vitrectomy surgery due to presence of vitreous hemorrhage at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring pars plana vitrectomy surgery due to traction retinal detachment at the end of the study.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Number of patients requiring pars plana vitrectomy surgery due to traction retinal detachment at the end of the study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline of how the eye feels as assessed by patient query.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of how the eye feels as assessed by patient query.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline of evaluation of corneal epithelium, bulbar and lower conjunctiva by biomicroscopy.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of evaluation of corneal epithelium, bulbar and lower conjunctiva by biomicroscopy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline of evaluation of vital signs (body temperature, pulse rate blood pressure and respiratory rate).</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Change from baseline of evaluation of vital signs (body temperature, pulse rate blood pressure and respiratory rate).</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of systemic exposure as measured by bioanalytic methods.</measure>
    <time_frame>Baseline - 24 weeks</time_frame>
    <description>Evaluation of systemic exposure as measured by bioanalytic methods.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Proliferative Diabetic Retinopathy (PDR)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% OC-10X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% OC-10X</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% OC-10X</intervention_name>
    <description>2% OC-10X</description>
    <arm_group_label>2% OC-10X</arm_group_label>
    <other_name>2-Biphenyl-4-yl-2,3-dihydro-(1H)-quinazolin-4-one</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male or female patients diagnosed with Proliferative Diabetic Retinopathy will be eligible
        if the following inclusion criteria are met:

          1. Ability to provide approved written informed consent and complies with study-related
             procedures/assessments for the full duration of the study, having age â‰¥18 years.

          2. Type 1 or Type 2 Diabetes Mellitus.

          3. Proliferative Diabetic Retinopathy (level 61, 65, 71, or 75) in one or both eyes
             without evidence of significant vitreous/pre retinal hemorrhage that would limit
             photographic documentation of area of neovascularization and without pre-retinal
             fibrosis. If both eyes meet eligibility requirements, the less affected eye will be
             selected to receive investigational drug or placebo. The second eye will be treated
             with the standard of care. (e.g. panretinal laser photocoagulation).

          4. Best-Corrected Visual acuity of 20/200 or better in each eye.

          5. If female and:

               -  Of childbearing potential, agrees to use an acceptable method of birth control as
                  judged by the Investigator(s), such as condoms, foams, jellies, diaphragm,
                  intrauterine device (IUD), for the duration of the study and for at least 2 weeks
                  following the final dose of study drug or abstinence; or

               -  Is postmenopausal for at least 1 year; or

               -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy).

               -  Is not pregnant or breastfeeding.

        Exclusion Criteria:

        Male or female patients diagnosed with Proliferative Diabetic Retinopathy will not be
        eligible in the study if any of the exclusion criteria are met:

          1. Clinically significant systemic diseases/conditions that, in the opinion of the
             Investigator, could negatively affect the safety of the patient during the study on a
             as determined on a case by case basis (e.g., unstable medical status including
             uncontrolled blood pressure, cardiovascular disease, uncontrolled liver disease,
             glycemic control or significant renal disease, defined as a history of chronic renal
             failure requiring dialysis or kidney transplant, hepatic, pulmonary, gastrointestinal
             or neurological diseases, cancer or BMI).

          2. Participation in any other clinical study/trial within the past 30 days prior to
             randomization.

          3. Current treatment for active systemic infection.

          4. Known allergy to any component of the formulation or to topical anesthetics (e.g.,
             benzalkonium chloride, fluorescein, etc.).

          5. History of any psychiatric illness, which may impair the ability to provide written
             informed consent.

          6. Presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses or syphilis
             infection.

          7. Positive for urinary screen testing of drugs of abuse (opiates, cannabinoids,
             amphetamines, barbiturates, benzodiazepines, cocaine).

          8. History of drug dependence or excessive alcohol intake on a habitual basis of more
             than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or
             1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the
             duration of each study period.

          9. Use of anti-mitotic or anti-metabolite therapy within 2 months of enrollment.

         10. Planned use of any ocular or systemic medications that the Investigator determines
             unacceptable during the study (i.e. anti-vascular endothelial growth factor [VEGF]
             therapy), with the exception of oral contraceptives and short-term use of
             over-the-counter analgesics during the study.

         11. Any other concurrent condition that, in the opinion of the Investigator, would prevent
             completion of the clinical trial, including inability to comply with the study
             requirements.

         12. Presence of significant fibrosis or gliosis of the neovascularization of the disc or
             retina.

         13. Presence of tractional retinal detachment.

         14. History of panretinal laser photocoagulation (PRP) for Proliferative Diabetic
             Retinopathy.

         15. Patients likely to require treatment for diabetic macular edema during the study.

         16. Any intraocular surgery or trauma within 6 months before trial enrollment.

         17. History of chronic ocular disease that, in the opinion of the Investigator, will
             affect neovascular progression.

         18. Myocardial infarction, other cardiac events requiring hospitalization, stroke,
             transient ischemic attack, or treatment for congestive heart failure within 6 months
             prior to randomization that, in the in the opinion of the Investigator, could
             negatively affect the safety of the patient during the study.

         19. Current use of contact lenses.

         20. Concurrent or anticipated use of ocular agents during the study period that are
             considered by the Investigator to interfere with the study objectives.

         21. History or evidence of ocular infection, inflammation, blepharitis, or conjunctivitis
             within 2 months; history of herpes simplex keratitis.

         22. An ocular condition is present (other than diabetes) that, in the opinion of the
             Investigator, might affect macular edema or alter visual acuity during the course of
             the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease,
             neovascular glaucoma, Irvine-Gass Syndrome, etc.).

         23. Substantial cataract that,

               -  In the opinion of the Investigator, is likely to be causing decreased visual
                  acuity by 3 lines or more (e.g.., cataract reducing acuity to 20/40 or worse).

               -  Would interfere with photography of the retina.

         24. Aphakia, uncontrolled glaucoma (in Investigator's judgment).

         25. Inability to tolerate eye drops in the eye or to have eye drops correctly
             administered.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia B Williams, PhD</last_name>
    <role>Study Director</role>
    <affiliation>OcuCure Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bangladesh Eye Hospital</name>
      <address>
        <city>Dhaka</city>
        <zip>1205</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

